Shanghai Securities News China Securities Network News (reporter Qiu Dekun) Saisheng Pharmaceutical announced at noon on December 16 that the company recently received a notice of acceptance of the registration of naphthalenemustazole mesylate for injection issued by the State Drug Administration, and the State Drug Administration reviewed the drug registration application for the above drugs in accordance with Article 32 of the Administrative Licensing Law of the People's Republic of China and decided to accept it.
Namusmust mesylate for injection is used to improve the acute symptoms of pancreatitis, to treat disseminated intravascular coagulation syndrome (DIC), and to prevent coagulation of perfusion of blood during extracorporeal circulation in patients with hemorrhagic lesions or bleeding tendencies (hemodialysis and plasmapheresis).
At the same time, naphtholistat mesylate is a new type of protease inhibitor, which has a strong and extensive inhibitory effect on trypsin, complement system, thrombolytic system and platelet aggregation. Pharmacological effects are exerted by reversibly inhibiting trypsin-like serine protease.
Saisheng Pharmaceutical inquired about the website of the State Food and Drug Administration and found that only Jiangsu Durui Pharmaceutical Co., Ltd. in China has obtained the drug approval number of naphtolimus mesylate for injection.
![Most people have two "holes" in their stomachs, but there are more than two of them[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)